The disease is systemic, not cosmetic—it reshapes how people sleep and see themselves.
Psoriasis diagnoses in Brazil's public health system grew 19.2% annually from 2019-2024, triple the pre-2019 rate, affecting skin, joints, nails and overall quality of life. Red plaques, nail changes, joint pain and itching are key symptoms; stress, infections, cold weather and certain medications trigger flare-ups in genetically predisposed individuals.
- 125 million people worldwide have psoriasis (2-3% of global population)
- Brazil's new diagnoses grew 19.2% annually from 2019-2024, triple the pre-2019 rate
- Three biologic drugs (adalimumab, secukinumab, ustequinumab) account for 80% of public system prescriptions
- Women typically diagnosed between ages 50-59; men diagnosed across wider range (44-64)
- 58% of physicians cite lack of public awareness as primary barrier to effective management
Brazil sees tripled growth in psoriasis diagnoses since 2019, with new biologic medications approved by Anvisa offering improved treatment outcomes for this chronic inflammatory disease affecting 125 million globally.
In May, Brazil's health regulator approved a new weapon against psoriasis and other chronic inflammatory diseases, reigniting conversation about a condition that affects far more people than most realize. The National Health Surveillance Agency authorized ustequinumab (marketed as Yesintek) for treating psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis—a milestone that underscores how much the landscape of managing these diseases has shifted in recent years.
Globally, psoriasis touches roughly 125 million people, somewhere between 2 and 3 percent of the world's population. Brazil's numbers tell a striking story. Research from Ipsos, a multinational market research firm, tracked how many Brazilians sought treatment through the public health system between 2019 and 2024. The growth was dramatic. From 2009 to 2019, new diagnoses climbed at an average annual rate of 6.1 percent, with patients already in treatment increasing at 7.5 percent yearly. Then something shifted. Between 2019 and 2024, those rates nearly tripled—new diagnoses jumped to 19.2 percent annually, while patients receiving ongoing care grew at 25 percent per year.
Psoriasis is not simply a skin problem, though that is where it announces itself most visibly. Dr. Maria de Fátima, a dermatologist at Afya Medical Education in Belo Horizonte, describes it as a chronic inflammatory disease rooted in immune system malfunction. The body's defenses accelerate skin cell turnover abnormally, and the consequences ripple outward: joints swell, nails deteriorate, the gut and eyes can suffer, and the emotional toll runs deep. The disease reshapes how people sleep, how they see themselves, how they move through the world.
The warning signs are recognizable once you know them. Red, scaly patches cluster on elbows, knees, the scalp, and lower back—sometimes spreading across larger areas, sometimes confined. The scales themselves are distinctive, silvery-white and thick. Itching and burning sensations range from mild to severe. Nails may separate from the nail bed, develop ridges, thicken, or show small pits. Joint pain can emerge, hinting at psoriatic arthritis. In skin folds—armpits, groin, under the breasts—lesions appear that doctors must carefully distinguish from fungal infections.
What triggers a flare varies person to person, but patterns emerge. Emotional stress is a common culprit. So are throat infections, physical trauma to the skin, smoking, heavy drinking, excess weight, poor sleep, and certain medications like lithium and beta-blockers. Abruptly stopping systemic corticosteroids can provoke an outbreak. Cold weather and dry skin amplify the problem. Dr. de Fátima emphasizes that each patient responds differently, making personalized medical oversight essential. Consistent treatment, healthy habits, and careful management of known triggers make the difference between frequent crises and extended periods of calm.
The treatment arsenal has transformed. Biologic medications now serve just over half of all psoriasis patients in Brazil's public system. Three drugs dominate the market, accounting for more than 80 percent of prescriptions: adalimumab, secukinumab, and ustequinumab. These newer therapies target the specific inflammatory pathways driving the disease, delivering faster results and fewer side effects than older treatments. Patients report not just clearer skin but better sleep, stronger self-esteem, and restored productivity. The emotional and social weight of the disease lifts.
Yet obstacles remain. The Ipsos study surveyed 164 specialist physicians and found that lack of public awareness ranks as the primary barrier—cited by 58 percent of doctors. Many patients wait until a crisis forces them to seek care, missing the chance for continuous inflammation control. Half the physicians surveyed point to difficulty catching the disease early as a major impediment to effective treatment. There are also demographic disparities: women and men are nearly equally affected, but women tend to receive their diagnosis later, typically between ages 50 and 59, while men's diagnoses spread across a wider age range from 44 to 64.
Misunderstandings cloud the picture. Psoriasis is not contagious—it does not spread through contact. It is not merely cosmetic. It is a systemic inflammatory disease with real consequences for the body and mind. Stress genuinely worsens it. There is no permanent cure, but the disease can be controlled well enough to achieve long stretches without symptoms. As treatment options multiply and awareness grows, the question becomes not whether psoriasis can be managed, but whether the people who need help will find it in time.
Citas Notables
The disease is not contagious, not merely cosmetic, but a systemic inflammatory condition with real consequences for body and mind.— Dr. Maria de Fátima, dermatologist
Recent therapeutic advances have transformed psoriasis management, delivering faster results, better safety profiles, and significant improvements in sleep, self-esteem, and quality of life.— Dr. Maria de Fátima, dermatologist
La Conversación del Hearth Otra perspectiva de la historia
Why did the approval of this one drug in May matter enough to restart the whole conversation about psoriasis in Brazil?
Because it signals that the toolkit keeps expanding. When you have more options, you can match treatment to the individual—what works for one person's immune system might not work for another. It's a sign the field is moving.
The numbers jumped dramatically after 2019. Was the disease suddenly getting worse, or were people finally getting diagnosed?
Probably both, honestly. Better awareness helps people recognize symptoms earlier. But there's also real growth in cases. The stress of the pandemic, the economic pressures—these things can trigger flares in people who carry the genetic predisposition.
You mentioned women get diagnosed later than men. Why would that be?
Women might dismiss early symptoms as minor skin irritation or attribute them to other causes. There's also less visibility of the disease in women's health conversations. By the time a woman reaches 50, the disease has often progressed further.
If the new drugs work so well, why are people still struggling?
Access is one thing, but awareness is bigger. Half of all doctors say early diagnosis is hard. If you don't know what to look for, you don't seek help. And many patients only show up when they're in crisis, not for prevention.
What's the most dangerous myth about psoriasis?
That it's contagious or that it's just vanity. When people think it's cosmetic, they don't take it seriously. They don't realize it's affecting their joints, their gut, their sleep, their ability to work. The disease is systemic.
So what changes the trajectory for someone with psoriasis?
Catching it early, staying consistent with treatment, managing stress, sleeping well, not smoking. And having a doctor who knows them, not just someone they see during a flare. Continuity of care is everything.